Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Vertex is just a few weeks away from hearing the FDA's verdict on its cystic fibrosis (CF) therapy Orkambi, so the publication of clinical trial data in a prestigious journal comes at an opportune ...

The UAB Gregory Fleming James Cystic Fibrosis Research Center is a university-wide interdisciplinary research center funded by the National Institutes of Health, the Cystic Fibrosis Foundation, and ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory ...

Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

The Baylor Medicine Maconda Brown O'Connor, Ph.D., Adult Cystic Fibrosis Center provides the highest quality ... Your participation provides data for healthcare improvement and research while helping ...